Copyright © 2003 American Medical Association. All rights reserved. From: Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic NephropathyThe Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA. 2003;290(16):2159-2167. doi:10.1001/jama.290.16.2159 Figure Legend: DCCT indicates Diabetes Control and Complications Trial; EDIC, Epidemiologyof Diabetes Interventions and Complications; HbA1c, glycosylatedhemoglobin. Boxes indicate 25th and 75th percentiles of HbA1c level;whiskers, 5th and 95th percentiles; heavy horizontal lines, medians; thinhorizontal lines, means. Date of download: 10/25/2017 Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved. From: Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic NephropathyThe Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA. 2003;290(16):2159-2167. doi:10.1001/jama.290.16.2159 Figure Legend: Microalbuminuria defined as albumin excretion rate ≥28 µg/min,equivalent to 40 mg/24 h. A, Prevalence at the end of the Diabetes Controland Complications Trial (DCCT) and during the Epidemiology of Diabetes Interventionsand Complications (EDIC) study. The differences between the 2 treatment groupsare significant at each time point after DCCT closeout (P<.001). B, Cumulative incidence of new cases in the EDIC studyfor those participants in the intensive- and conventional-treatment groupswith normal albuminuria at the beginning and end of the DCCT. The differencein cumulative incidences is significant by the log-rank test (P<.001). Date of download: 10/25/2017 Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved. From: Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic NephropathyThe Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA. 2003;290(16):2159-2167. doi:10.1001/jama.290.16.2159 Figure Legend: Albuminuria defined as albumin excretion rate ≥208 µg/min,equivalent to 300 mg/24 h. A, Prevalence of clinical albuminuria at the endof the Diabetes Control and Complications Trial (DCCT) and during the Epidemiologyof Diabetes Interventions and Complications (EDIC) study. The differencesbetween the treatment groups are significant at each time point after DCCTclose-out (P<.01). B, Cumulative incidence ofnew cases in the EDIC study for those participants in the intensive- and conventional-treatmentgroups with either normoalbuminuria or microalbuminuria at the end of theDCCT. The difference in cumulative incidences is significant by the log-rank-test.(P<.001). Date of download: 10/25/2017 Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved. From: Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic NephropathyThe Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA. 2003;290(16):2159-2167. doi:10.1001/jama.290.16.2159 Figure Legend: Prevalence of hypertension (defined as blood pressure >140/90 mmHg) at the end of the Diabetes Control and Complications Trial (DCCT) andduring the Epidemiology of Diabetes Interventions and Complications (EDIC)study for participants in the intensive vs conventional-treatment groups.The aggregate odds reduction with intensive vs conventional therapy of emergenthypertension during the EDIC study, adjusted for DCCT mean arterial pressure,was 40.4% (95% confidence interval, 33.7%-46.5%; P<.001). Date of download: 10/25/2017 Copyright © 2003 American Medical Association. All rights reserved.